AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27435303
Drug: Intravenous fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fish oil (FO) supplementation after the first week of PN
Trial: 24766295
Drug: Rikkunshito (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rikkunshito (2.5 g three times a day for 8 weeks)
Trial: 22926604
Drug: Quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine XR (50 to 300 mg/d, mean = 132.2 mg)
Trial: 15050907
Drug: Alendronate (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (40 mg daily in 3-month blocks)
Trial: 15050907
Drug: Pamidronate (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (60 mg every 3 months as a single infusion)
Trial: 15050907
Drug: Alendronate (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (40 mg daily) in previously untreated patients
Trial: 15050907
Drug: Alendronate (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (40 mg daily) in previously treated patients
Trial: 7761376
Drug: Combination levorin
RxNorm normalized name: Levorin
DrugBank: Candicidin (DB01152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination levorin + furadonin + nitroxoline
Trial: 28738708
Drug: HBB 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBB 40 mg
Trial: 23116377
Drug: Children's Psychosocial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children's Psychosocial Rehabilitation Treatment Adherence Measure (CTAM) for CPSR
Trial: 23116377
Drug: Children's Psychosocial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children's Psychosocial Rehabilitation Treatment Adherence Measure (CTAM) for psychotherapy
Trial: 18705532
Drug: Fixed-dose amlodipine/benazepril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose amlodipine/benazepril (2.5/5 mg/day titrated to 5/10 mg/day)
Trial: 18705532
Drug: Amlodipine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine monotherapy (5 mg/day titrated to 10 mg/day)
Trial: 18705532
Drug: Fixed-dose amlodipine/benazepril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose amlodipine/benazepril
Trial: 14564289
Drug: 7-mm tub
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-mm tub preparation design
Trial: 14564289
Drug: 11-mm tub
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11-mm tub preparation design
Trial: 14564289
Drug: 7-mm box
RxNorm normalized name: ALLERGENIC EXTRACT, BOX ELDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-mm box preparation design
Trial: 14564289
Drug: 11-mm box
RxNorm normalized name: ALLERGENIC EXTRACT, BOX ELDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11-mm box preparation design
Trial: 14564289
Drug: Box-shaped tooth
RxNorm normalized name: Sus scrofa tooth preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Box-shaped tooth preparation
Trial: 10791875
Drug: Nucleoside analog
RxNorm normalized name: Nucleoside analog
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nucleoside analog therapies
Trial: 1363481
Drug: Verapamil (increased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (increased dose from 240 to 600 mg)
Trial: 2879444
Drug: Nifedipine (50.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (50.0 ± 5.2 mg per day) + Atenolol (89.5 ± 25.7 mg per day)
Trial: 2879444
Drug: Verapamil (460
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (460 ± 20 mg per day) + Enalapril (29.5 ± 5.0 mg per day)
Trial: 2879444
Drug: Nifedipine (50.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (50.0 ± 5.2 mg per day)
Trial: 2879444
Drug: Verapamil (460
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (460 ± 20 mg per day)
Trial: 25089359
Drug: ACN-rich beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACN-rich beverage (juice with 983.7 mg/l ACN)
Trial: 25089359
Drug: ACN-rich beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACN-rich beverage (smoothie with 840.9 mg/l ACN)
Trial: 18717508
Drug: Oxymorphone immediate-release
RxNorm normalized name: oxymorphone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymorphone immediate-release (IR)
Trial: 18717508
Drug: Oxymorphone extended-release
RxNorm normalized name: oxymorphone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymorphone extended-release (ER)
Trial: 18717508
Drug: Titrated doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titrated doses of oxymorphone ER
Trial: 16365493
Drug: Buffered prilocaine
RxNorm normalized name: Prilocaine
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buffered prilocaine (10 ml of prilocaine hydrochloride 2% buffered with 1 ml of sodium bicarbonate 8.4%)
Trial: 16365493
Drug: Plain prilocaine
RxNorm normalized name: Prilocaine
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plain prilocaine (10 ml of plain prilocaine hydrochloride 2% solution)
Trial: 14644397
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of atorvastatin 80 mg QD and avasimibe 750 mg QD
Trial: 11021899
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg b.i.d. for 7 days (first phase)
Trial: 11021899
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg o.m. for 2 weeks (second phase)
Trial: 8626843
Drug: Testosterone transdermal
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone transdermal system applied to the back for 24 hours
Trial: 8626843
Drug: Testosterone transdermal
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone transdermal system applied to various sites (abdomen, back, chest, shin, thigh, upper arm) for 24 hours
Trial: 1576117
Drug: D,L‐α‐tocopherol (vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D,L‐α‐tocopherol (vitamin E) 1,000 IU/day for 7 days
Trial: 6374766
Drug: Endocervical prostaglandin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocervical prostaglandin E2 gel (0.5 mg in 2.5 ml)
Trial: 6374766
Drug: Vaginal PGE2
RxNorm normalized name: dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Vaginal PGE2 tablet (2.0 mg)
Trial: 6374766
Drug: Endocervical prostaglandin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocervical prostaglandin E2 gel (0.5 mg) in women with Bishop score 0-2
Trial: 6374766
Drug: Vaginal PGE2
RxNorm normalized name: dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Vaginal PGE2 tablet (2.0 mg) in women with Bishop score 0-2
Trial: 31662396
Drug: Telemonitoring using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telemonitoring using Sense4Baby CTG devices, Microlife BP monitor, daily telephone calls with an obstetric healthcare professional, and weekly hospital visits.
Trial: 22834725
Drug: Psychodynamic or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychodynamic or psychoanalytically oriented treatments (PAT), up to 80 sessions in the first year, potentially extended to 240-300 sessions over two to three years.
Trial: 22834725
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT), up to 60 sessions in the first year, potentially extended to 80 sessions focusing on maintenance and relapse prevention.
Trial: 8858222
Drug: Hyperglycaemia (blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycaemia (blood glucose 12-15 mmol/l)
Trial: 1634643
Drug: Test preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test preparation (20 mg isosorbide-5-mononitrate)
Trial: 1634643
Drug: Reference preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference preparation (20 mg isosorbide-5-mononitrate)
Trial: 6519164
Drug: Piretanide (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piretanide (12 to 192 mg)
Trial: 28003206
Drug: Dietary zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary zinc increase from 6 mg Zn/d to 10 mg Zn/d for 4 weeks
Trial: 21401921
Drug: Topiramate (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (up to 75 mg per day) with psychotherapy (n = 30)
Trial: 18492379
Drug: diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: diclofenac sodium suppository 100 mg (Voltarol) at the end of oocyte retrieval
Trial: 17176187
Drug: Multidimensional family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidimensional family therapy with family-focused techniques
Trial: 17176187
Drug: Multidimensional family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidimensional family therapy with adolescent-focused techniques
Trial: 10883827
Drug: Antibiotic prescribed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prescribed according to culture and sensitivity (Group A)
Trial: 3535860
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of lignocaine-prilocaine cream (EMLA)
Trial: 24201696
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg perindopril daily for 20 weeks
Trial: 20220293
Drug: Intramuscular testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular testosterone undecanoate (im TU)
Trial: 20220293
Drug: Oral testosterone
RxNorm normalized name: testosterone Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral testosterone undecanoate (oral TU)
Trial: 20220293
Drug: Transdermal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal placebo gel (P)
Trial: 11016387
Drug: Cryoablation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryoablation therapy
Trial: 11016387
Drug: Intercostal application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intercostal application of local anesthetic agents (Control)
Trial: 8879616
Drug: Purged PBPC
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Purged PBPC (75 micrograms/ml of ether lipid for 4 h at 37 degrees C)
Trial: 23725995
Drug: Cardiac resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronization therapy (CRT) with implantable cardioverter defibrillator (ICD), n = 132
Trial: 23725995
Drug: Cardiac resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronization therapy (CRT) with ICD, n = 132
Trial: 21418447
Drug: Nutritional supplementation
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplementation (cereal-lentil mixture providing 930 kcal and multivitamin micronutrient supplement)
Trial: 19655825
Drug: OAC plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC plus atorvastatin 40 mg/day and ezetimibe 10 mg/day
Trial: 18247250
Drug: Treatment Implementation
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Implementation (TI) methods in a rehabilitation team‐training intervention
Trial: 14760792
Drug: Tacrolimus 3
RxNorm normalized name: Tacrolimus 300 microgram/g cutaneous ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus 3 mg/day
Trial: 14760792
Drug: Tacrolimus 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus 1.5 mg/day
Trial: 9661016
Drug: DU-6859a 50
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DU-6859a 50 mg b.i.d. for 5 days
Trial: 9661016
Drug: DU-6859a 100
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DU-6859a 100 mg b.i.d. for 5 days
Trial: 9661016
Drug: Theophylline (TP)
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline (TP) 200 mg b.i.d. for 9 days
Trial: 7595905
Drug: Losartan-HCTZ combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan-HCTZ combination therapy
Trial: 7595905
Drug: Losartan (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (both monotherapy and combination therapy)
Trial: 31612482
Drug: Erenumab 28
RxNorm normalized name: ERENUMAB
DrugBank: Erenumab (DB14039)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Erenumab 28 mg
Trial: 21514032
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal progesterone once daily for 14 days after insemination
Trial: 18444848
Drug: Daptomycin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daptomycin (4 mg/kg) once daily for 5-14 days
Trial: 18444848
Drug: Ceftriaxone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (2 g) once daily for 5-14 days
Trial: 18444848
Drug: Daptomycin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daptomycin (4 mg/kg) once daily for 5-14 days with prior effective therapy
Trial: 18444848
Drug: Ceftriaxone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (2 g) once daily for 5-14 days with prior effective therapy
Trial: 16596465
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose risperidone
Trial: 11094588
Drug: Rapacuronium 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapacuronium 2.0 mg kg-1
Trial: 11094588
Drug: Rapacuronium 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapacuronium 2.5 mg kg-1
Trial: 11094588
Drug: Succinylcholine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine 1.0 mg kg-1
Trial: 11094588
Drug: Rapacuronium 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapacuronium 2.0 mg kg-1 vs Succinylcholine
Trial: 11094588
Drug: Rapacuronium 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapacuronium 2.5 mg kg-1 vs Succinylcholine
Trial: 11094588
Drug: Rapacuronium (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapacuronium (both doses)
Trial: 1723288
Drug: Early consolidation
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early consolidation therapy with 6 courses of CVP (cyclophosphamide, vincristine, prednisone) given monthly
Trial: 1723288
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy with cyclophosphamide and prednisone given every 6 weeks for 2 years
Trial: 7468581
Drug: Four doses
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four doses of human diploid cell strains rabies vaccine (HDCV) administered in three days
Trial: 7468581
Drug: Four doses
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four doses of human diploid cell strains rabies vaccine (HDCV) administered in 14 days
Trial: 17486918
Drug: Single bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single bolus of neuromuscular blocking drug (rocuronium) at induction
Trial: 17486918
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of neuromuscular blocking drugs
Trial: 15606435
Drug: Lornoxicam (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam (8 mg single oral dose)
Trial: 7777246
Drug: Ondansetron administered
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron administered in group A: 8 mg IV infusion over 10 min before CDDP, followed by 8 mg orally every 8 h for 3 days.
Trial: 7777246
Drug: Ondansetron administered
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron administered in group B: six intravenous doses every 6 h starting 12.5 h before cisplatin, followed by 8 mg orally every 6 h for 3 days.
Trial: 2225876
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg urapidil infusion
Trial: 21090333
Drug: Medication (Antine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (Antine Capsule, diclofenac sodium, 50 mg, twice daily)
Trial: 19192762
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of tramadol in 3‐mL saline
Trial: 15903126
Drug: Ximelagatran (24,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ximelagatran (24, 36, 48, or 60 mg twice daily for 12 to 16 days)
Trial: 10346073
Drug: Sequential assignment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential assignment (SA)
Trial: 1659239
Drug: Pentamidine injections
RxNorm normalized name: pentamidine Injection
DrugBank: Pentamidine (DB00738)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentamidine injections followed by 20 days of sodium stibogluconate therapy
Trial: 1659239
Drug: Pentamidine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentamidine (5 additional injections) followed by a course of antimony therapy
Trial: 6797298
Drug: Cimetidine 200
RxNorm normalized name: cimetidine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 200 mg + Oxyphenonium bromide 10 mg
Trial: 31842950
Drug: Tetramethylpyrazine (TMP)
RxNorm normalized name: Tetramethylpyrazine
DrugBank: Ligustrazine (DB19074)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetramethylpyrazine (TMP) 100 mg orally three times a day for 16 weeks
Trial: 26175552
Drug: Bowel preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bowel preparation (BP)
Trial: 26175552
Drug: Non-bowel preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-bowel preparation (NP)
Trial: 9504599
Drug: Melatonin 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 3.0 mg nightly for 30 days
Trial: 1239216
Drug: Bupivacaine and
RxNorm normalized name: bupivacaine and meloxicam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine and saline solution
Trial: 21639660
Drug: No videotape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No videotape treatment-as-usual
Trial: 12876237
Drug: Entacapone 200
RxNorm normalized name: entacapone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entacapone 200 mg with each daily levodopa dose
Trial: 8712328
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 0.0625% bupivacaine with either 2.5 micrograms.ml‐1 fentanyl or 0.25 micrograms.ml‐1 sufentanil
Trial: 30821716
Drug: Sustained nicorandil
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained nicorandil administration (5 mg, three times daily)
Trial: 30821716
Drug: Single nicorandil
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single nicorandil administration before PCI (control group)
Trial: 30821716
Drug: Sustained nicorandil
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained nicorandil administration
Trial: 21864866
Drug: Insulin and
RxNorm normalized name: Isophane insulin and porcine regular insulin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin and glucose administration
Trial: 3915155
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose 250 mg mefloquine
Trial: 3915155
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose 500 mg mefloquine
Trial: 3915155
Drug: Standard 3-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 3-day treatment with 1,500 mg chloroquine
Trial: 30865324
Drug: Strong Hearts,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strong Hearts, Healthy Communities (SHHC) intervention; met 1 hour twice a week for 24 weeks, involving aerobic exercise and progressive strength training.
Trial: 20929110
Drug: HTK solution
RxNorm normalized name: Custodial HTK Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTK solution (nonflushed)
Trial: 20929110
Drug: HTK solution
RxNorm normalized name: Custodial HTK Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTK solution (flushed)
Trial: 15661405
Drug: Purging with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purging with 25 mug/mL ET‐18‐OCH3 combined with cryopreservation at 10% DMSO and hyperthermia at 42 degrees C combined with cryopreservation at 10% or 4% DMSO
Trial: 12232643
Drug: 0.01 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01 mg/kg cisatracurium (Cis 6 group: pretreatment interval 6 min)
Trial: 12232643
Drug: 0.01 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01 mg/kg cisatracurium (Cis 3 group: pretreatment interval 3 min)